190 related articles for article (PubMed ID: 29387553)
1. Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots.
Abrahamsson PA
Asian J Urol; 2017 Oct; 4(4):208-222. PubMed ID: 29387553
[TBL] [Abstract][Full Text] [Related]
2. Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.
Dason S; Allard CB; Wang JG; Hoogenes J; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):28-36. PubMed ID: 24775721
[TBL] [Abstract][Full Text] [Related]
3. Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research.
Parikh RA; Pascal LE; Davies BJ; Wang Z
Asian J Androl; 2014; 16(4):505-10. PubMed ID: 24759577
[TBL] [Abstract][Full Text] [Related]
4. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract][Full Text] [Related]
5. Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
Wolff JM; Abrahamsson PA; Irani J; da Silva FC
BJU Int; 2014 Oct; 114(4):476-83. PubMed ID: 24433259
[TBL] [Abstract][Full Text] [Related]
6. Real-World Practice Patterns and Predictors of Continuous versus Intermittent Androgen Deprivation Therapy Use for Prostate Cancer in Older Men.
Cheung DC; Alibhai SMH; Martin LJ; Komisarenko M; Dharma C; Warde P; Sridhar SS; Fleshner NE; Kulkarni GS; Finelli A
J Urol; 2021 Oct; 206(4):933-941. PubMed ID: 34032504
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis.
Tsai HT; Penson DF; Makambi KH; Lynch JH; Van Den Eeden SK; Potosky AL
Urology; 2013 Aug; 82(2):327-33. PubMed ID: 23896094
[TBL] [Abstract][Full Text] [Related]
8. [Risks of diabetes mellitus and impaired glucose tolerance induced by intermittent versus continuous androgen-deprivation therapy for advanced prostate cancer].
Zeng S; Li ZP; Li W; Pu WZ; Liu P; Ma ZF
Zhonghua Nan Ke Xue; 2017 Jul; 23(7):598-602. PubMed ID: 29723451
[TBL] [Abstract][Full Text] [Related]
9. Population-based Assessment of Intermittent Androgen Deprivation Therapy Utilization for Relapsed, Nonmetastatic, Hormone-sensitive Adenocarcinoma of the Prostate.
Janzen BW; Ong A; Penner M; Koul R; Dubey A; Ahmed S; Bashir B; Chowdhury A; Dawe DE; Nayak J; Kim JO
Am J Clin Oncol; 2020 Dec; 43(12):865-871. PubMed ID: 32976179
[TBL] [Abstract][Full Text] [Related]
10. Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach.
Bonfill X; Arevalo-Rodriguez I; Martínez García L; Quintana MJ; Buitrago-Garcia D; Lobos Urbina D; Cordero JA
Cancer Manag Res; 2018; 10():2357-2367. PubMed ID: 30122985
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of testosterone during androgene deprivation therapy].
Vallat A; Pillot P; Lebâcle C; Irani J
Prog Urol; 2019 Sep; 29(10):510-523. PubMed ID: 31311715
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
[TBL] [Abstract][Full Text] [Related]
13. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
Magnan S; Zarychanski R; Pilote L; Bernier L; Shemilt M; Vigneault E; Fradet V; Turgeon AF
JAMA Oncol; 2015 Dec; 1(9):1261-9. PubMed ID: 26378418
[TBL] [Abstract][Full Text] [Related]
14. Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride.
Garcia RR; Masoodi KZ; Pascal LE; Nelson JB; Wang Z
Am J Clin Exp Urol; 2014; 2(1):82-91. PubMed ID: 25374909
[TBL] [Abstract][Full Text] [Related]
15. A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy.
DeJongh J; Ahsman M; Snelder N
J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):465-477. PubMed ID: 33538922
[TBL] [Abstract][Full Text] [Related]
16. Intermittent androgen deprivation therapy: redefining the standard of care?
Shore ND; Crawford ED
Rev Urol; 2010; 12(1):1-11. PubMed ID: 20428288
[TBL] [Abstract][Full Text] [Related]
17. Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model.
Wang Y; Gupta S; Hua V; Ramos-Garcia R; Shevrin D; Jovanovic BD; Nelson JB; Wang Z
Prostate; 2010 Feb; 70(2):147-54. PubMed ID: 19739129
[TBL] [Abstract][Full Text] [Related]
18. International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.
Liede A; Hallett DC; Hope K; Graham A; Arellano J; Shahinian VB
ESMO Open; 2016; 1(2):e000040. PubMed ID: 27843596
[TBL] [Abstract][Full Text] [Related]
19. New Protocol of Intermittent Androgen Deprivation Therapy for Patients With Metastatic Prostate Cancer: A Retrospective Study.
Cai J; Feng G; Yan Y; Liu Z; Jing S
Clin Genitourin Cancer; 2019 Dec; 17(6):e1129-e1136. PubMed ID: 31594735
[TBL] [Abstract][Full Text] [Related]
20. Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer.
Lu Y; Chu Q; Li Z; Wang M; Gatenby R; Zhang Q
Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38493345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
